7,8-Dimethylhypoxanthin | 58192-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7,8-Dimethylhypoxanthin
• 英文别名: 7,8-dimethyl-1,7-dihydro-purin-6-one；7,8-Dimethyl-1H-purin-6(7H)-one；7,8-dimethyl-1H-purin-6-one
• CAS: 58192-87-3
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: FVRXFPCSOCLHAU-UHFFFAOYSA-N

物化性质

• 熔点：
  290 °C (decomp)
• 沸点：
  486.3±18.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-amino-1,2-dimethyl-1H-imidazole-5-carboxylic acid ethyl ester 、 甲酰胺 以57%的产率得到
  参考文献：
  名称：

  EDENHOFER A., HELV. CHIM. ACTA , 1975, 58, NO 7, 2192-2209

  摘要：

  DOI：

文献信息

• OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20190284179A1

  公开（公告）日：2019-09-19

  The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R 1 , R 4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  这项发明涉及以下式I的化合物： 以及其药学上可接受的盐，其中A、X、R 1 、R 4 和n如本文所定义。此外，本发明涉及制造和使用式I化合物的方法，以及含有这些化合物的药物组合物。这些化合物可能在治疗由TRPA1介导的疾病和症状方面有用，如疼痛。
• Oxadiazole transient receptor potential channel inhibitors
  申请人：Genentech, Inc.

  公开号：US10710994B2

  公开（公告）日：2020-07-14

  The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及式 I 的化合物： 及其药学上可接受的盐，其中 A、X、R1、R4 和 n 如本文所定义。此外，本发明还涉及式 I 化合物的制造方法和使用方法，以及含有此类化合物的药物组合物。这些化合物可用于治疗由 TRPA1 介导的疾病和病症，如疼痛。
• [EN] OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DE CANAL À POTENTIEL DE RÉCEPTEUR TRANSITOIRE À BASE D'OXADIAZOLE
  申请人：GENENTECH INC

  公开号：WO2019182925A1

  公开（公告）日：2019-09-26

  The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1?, R4? and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.